Portolan Capital Management LLC Purchases New Stake in TransMedics Group, Inc. $TMDX

Portolan Capital Management LLC acquired a new position in TransMedics Group, Inc. (NASDAQ:TMDX) in the 3rd quarter, HoldingsChannel.com reports. The firm acquired 68,910 shares of the company’s stock, valued at approximately $7,732,000.

A number of other institutional investors have also recently bought and sold shares of the business. Whittier Trust Co. of Nevada Inc. lifted its position in shares of TransMedics Group by 981.0% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 227 shares of the company’s stock worth $26,000 after purchasing an additional 206 shares in the last quarter. Salomon & Ludwin LLC acquired a new stake in shares of TransMedics Group during the third quarter worth approximately $28,000. Optiver Holding B.V. grew its position in TransMedics Group by 248.1% during the third quarter. Optiver Holding B.V. now owns 268 shares of the company’s stock valued at $30,000 after purchasing an additional 191 shares in the last quarter. LOM Asset Management Ltd purchased a new position in TransMedics Group during the third quarter valued at approximately $34,000. Finally, Elevation Point Wealth Partners LLC acquired a new position in TransMedics Group in the 2nd quarter valued at approximately $48,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director Stephanie Lovell sold 1,193 shares of the firm’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $149.62, for a total transaction of $178,496.66. Following the transaction, the director owned 2,866 shares in the company, valued at approximately $428,810.92. This trade represents a 29.39% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director David Weill sold 3,571 shares of TransMedics Group stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $146.82, for a total transaction of $524,294.22. Following the completion of the sale, the director directly owned 12,134 shares of the company’s stock, valued at approximately $1,781,513.88. The trade was a 22.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 16,205 shares of company stock valued at $2,353,002. 7.00% of the stock is owned by company insiders.

Analysts Set New Price Targets

TMDX has been the subject of a number of research reports. Stifel Nicolaus lifted their target price on shares of TransMedics Group from $115.00 to $130.00 and gave the company a “hold” rating in a research note on Monday, March 9th. Needham & Company LLC upped their price target on shares of TransMedics Group from $166.00 to $174.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. Wall Street Zen lowered TransMedics Group from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. Canaccord Genuity Group lifted their price objective on TransMedics Group from $147.00 to $148.00 and gave the company a “buy” rating in a research report on Wednesday, December 17th. Finally, Piper Sandler boosted their target price on TransMedics Group from $140.00 to $160.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. Six investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $152.33.

TransMedics Group Price Performance

Shares of TMDX opened at $123.48 on Friday. The firm has a market cap of $4.24 billion, a PE ratio of 25.20 and a beta of 1.98. The firm’s 50 day moving average price is $135.92 and its 200 day moving average price is $127.19. The company has a debt-to-equity ratio of 1.06, a quick ratio of 6.59 and a current ratio of 7.14. TransMedics Group, Inc. has a twelve month low of $62.23 and a twelve month high of $156.00.

TransMedics Group Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.